Search results for "Delayed-Action Preparations"

showing 10 items of 101 documents

Swellable microparticles containing Suprofen: evaluation of in vitro release and photochemical behaviour

1998

Suprofen, an anti-inflammatory drug was incorporated in polymer networks based on biocompatible macromolecules, such as alpha,beta-polyasparthydrazide (PAHy) and alpha,beta-poly(N-hydroxyethyl)-DL-aspartamide (PHEA) crosslinked by glutaraldehyde or gamma-rays, respectively. Swelling tests carried out in aqueous media showed that pH value affects the swelling degree of the prepared hydrogels. In vitro release tests were performed in simulated gastrointestinal fluids (pH 1/6.8) using the pH variation method and in phosphate-buffered saline, pH 7.4. Experimental data indicated that Suprofen was released in a sustained way both from PAHy and PHEA microparticles. Further, incorporation of Suprof…

ErythrocytesPlasma SubstitutesSuprofenPharmaceutical ScienceSuprofenHemolysisDosage formchemistry.chemical_compoundmedicineHumansOrganic chemistryParticle SizeActive ingredientGastric JuicePhotosensitizing AgentsChromatographyAnti-Inflammatory Agents Non-SteroidalHydrogen-Ion ConcentrationNylonsCross-Linking ReagentsHydrazineschemistryGlutaralDelayed-Action PreparationsSelf-healing hydrogelsLiberationGlutaraldehydeSwellingmedicine.symptomPeptidesDrug carrierGelsmedicine.drugJournal of Controlled Release
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7…

ExacerbationReviewQuinoloneslaw.inventionPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineRandomized controlled trialsystematic reviewlaw030212 general & internal medicineCOPDLABA LAMA fixed-dose combination COPD systematic reviewbiologyHealth PolicyOlodaterolLAMAGeneral MedicineLamaRespiratory Function Testsfixed-dose combinationDrug CombinationsTreatment OutcomeIndanssystematic review.hormones hormone substitutes and hormone antagonistsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationLABA; LAMA; fixed-dose combination; COPD; systematic reviewLABAMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansCOPDAdverse effectAdrenergic beta-2 Receptor Agonistslcsh:RC705-779business.industryPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemCOPD; LABA; LAMA; fixed-dose combination; systematic reviewmedicine.diseasebiology.organism_classificationGlycopyrrolate030228 respiratory systemchemistryDelayed-Action PreparationsIndacaterolbusiness
researchProduct

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct

Gated mesoporous silica nanoparticles for the controlled delivery of drugs in cancer cells

2015

In recent years, mesoporous silica nanoparticles (MSNs) have been used as effective supports for the development of controlled-release nanodevices that are able to act as multifunctional delivery platforms for the encapsulation of therapeutic agents, enhancing their bioavailability and overcoming common issues such as poor water solubility and poor stability of some drugs. In particular, redox-responsive delivery systems have attracted the attention of scientists because of the intracellular reductive environment related to a high concentration of glutathione (GSH). In this context, we describe herein the development of a GSH-responsive delivery system based on poly(ethylene glycol)- (PEG-)…

INGENIERIA DE LA CONSTRUCCIONCell SurvivalIntracellular SpaceNanoparticleNanotechnologyAntineoplastic AgentsCONTROLLED-RELEASETRIGGERED RELEASEPolyethylene Glycolschemistry.chemical_compoundINORGANIC NANOPARTICLESQUIMICA ORGANICASYSTEMSPEG ratioQUIMICA ANALITICAElectrochemistrymedicinePOLYMER HYBRID NANOPARTICLESGLUTATHIONEBIOQUIMICA Y BIOLOGIA MOLECULARHumansGeneral Materials ScienceDoxorubicinSpectroscopyDrug CarriersENHANCED PERMEABILITYQUIMICA INORGANICASurfaces and InterfacesGlutathioneIN-VITROMesoporous silicaCondensed Matter PhysicsSilicon DioxideControlled releaseGUEST MOLECULESBioavailabilityDrug LiberationchemistryDoxorubicinDelayed-Action PreparationsDrug DesignNanoparticlesPhenazinesSUPPORTSEthylene glycolOxidation-ReductionPorositymedicine.drugHeLa Cells
researchProduct

Enhanced antifungal efficacy of tebuconazole using gated pH-driven mesoporous nanoparticles

2014

N&amp;uacute;ria Mas,1&amp;ndash;3 Irene Galiana,3 Silvia Hurtado,&amp;dagger; Laura Mondrag&amp;oacute;n,1&amp;ndash;3 Andrea Bernardos,1&amp;ndash;3 F&amp;eacute;lix Sancen&amp;oacute;n,1&amp;ndash;3 Mar&amp;iacute;a D Marcos,1&amp;ndash;3 Pedro Amor&amp;oacute;s,4 Nuria Abril-Utrillas,5 Ram&amp;oacute;n Mart&amp;iacute;nez-M&amp;aacute;&amp;ntilde;ez,1&amp;ndash;3 Jos&amp;eacute; Ram&amp;oacute;n Murgu&amp;iacute;a1,3 1Centro de Reconocimiento Molecular y Desarrollo Tecnol&amp;oacute;gico (IDM), Centro Mixto Universidad Polit&amp;eacute;cnica de Valencia, Universidad de Valencia, Valencia, Spain; 2Departamento de Qu&amp;iacute;mica, Universidad Polit&amp;eacute;cnica de Valencia, Valenci…

INGENIERIA DE LA CONSTRUCCIONMaterials scienceAntifungal AgentsPH-responsive nanoparticlesCell Survivalmedia_common.quotation_subjectCapped mesoporous nanoparticlesBiophysicsPharmaceutical ScienceNanoparticleBioengineeringSaccharomyces cerevisiaeNanocapsulesBiomaterialsDiffusionchemistry.chemical_compoundNanoporesQUIMICA ORGANICANanocapsulesInternational Journal of NanomedicineDrug DiscoveryQUIMICA ANALITICABIOQUIMICA Y BIOLOGIA MOLECULARFluoresceinParticle SizeCytotoxicityInternalizationmedia_commonTebuconazoleOriginal ResearchIntracellular releaseOrganic ChemistryQUIMICA INORGANICADrug SynergismGeneral MedicineMesoporous silicaHydrogen-Ion ConcentrationTriazoleschemistryBiochemistryDelayed-Action PreparationsBiophysicsTebuconazole loadingMesoporous materialPorosityInternational Journal of Nanomedicine
researchProduct

Enzyme-Responsive Intracellular Controlled Release Using Nanometric Silica Mesoporous Supports Capped with "Saccharides"

2010

The synthesis of new capped silica mesoporous nanoparticles for on-command delivery applications is described. The gate-like functional hybrid systems consisted of nanoscopic MCM-41-based materials functionalized on the pore outlets with different “saccharide” derivatives and a dye contained in the mesopores. A series of hydrolyzed starch products as saccharides were selected. The mesoporous silica nanoparticles S1, S2, and S3 containing the grafted starch derivatives Glucidex 47, Gludicex 39, and Glucidex 29 were synthesized. Additionally, for comparative purposes solid S4 containing lactose was prepared. Delivery studies in pure water in the presence of pancreatin or -D-galactosidase were…

INGENIERIA DE LA CONSTRUCCIONMaterials scienceTECNOLOGIA DE ALIMENTOSSwineStarchIntracellular SpaceCarbohydratesGatecarbohydratesGeneral Physics and AstronomyNanoparticleMesoporousKluyveromycesHydrolysischemistry.chemical_compoundAdsorptionQUIMICA ORGANICAgateAnimalsHumansOrganic chemistryGeneral Materials ScienceDrug CarriersQUIMICA INORGANICAGeneral EngineeringMesoporous silicaSilicon Dioxidebeta-GalactosidaseControlled releaseNanostructuresIntracellular controlled releaseMesoporous organosilicaenzymechemistryChemical engineeringEnzymeDelayed-Action Preparationsintracellular controlled releaseLLC-PK1 CellsAdsorptionMesoporous materialmesoporousPorosityHeLa Cells
researchProduct

In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model.

2015

Our aim is to develop and to validate the in situ closed loop perfusion method in rat colon and to compare with small intestine and Caco-2 cell models. Correlations with human oral fraction absorbed (Fa) and human colon fraction absorbed (Fa_colon) were developed to check the applicability of the rat colon model for controlled release (CR) drug screening. Sixteen model drugs were selected and their permeabilities assessed in rat small intestine and colon, and in Caco-2 monolayers. Correlations between colon/intestine/Caco-2 permeabilities versus human Fa and human Fa_colon have been explored to check model predictability and to apply a BCS approach in order to propose a cut off value for CR…

In situAbsorption (pharmacology)MalePathologymedicine.medical_specialtyColonCellPharmaceutical SciencePermeabilityCell Line TumorIntestine SmallmedicineAnimalsHumansRats Wistarbusiness.industryBiological TransportControlled releaseMolecular biologydigestive system diseasesSmall intestineRatsPerfusionmedicine.anatomical_structureIntestinal AbsorptionCaco-2Paracellular transportDelayed-Action PreparationsModels AnimalCaco-2 CellsbusinessPerfusionJournal of pharmaceutical sciences
researchProduct

In situ formation of steroidal supramolecular gels designed for drug release

2013

In this work, a steroidal gelator containing an imine bond was synthesized, and its gelation behavior as well as a sensitivity of its gels towards acids was investigated. It was shown that the gels were acid-responsive, and that the gelator molecules could be prepared either by a conventional synthesis or directly in situ during the gel forming process. The gels prepared by both methods were studied and it was found that they had very similar macroand microscopic properties. Furthermore, the possibility to use the gels as carriers for aromatic drugs such as 5-chloro-8-hydroxyquinoline, pyrazinecarboxamide, and antipyrine was investigated and the prepared two-component gels were studied with…

In situMagnetic Resonance SpectroscopykolesteroliImineSupramolecular chemistryPharmaceutical ScienceArticleChloroquinolinolsAnalytical ChemistryDelayed-Action Preparationslcsh:QD241-441chemistry.chemical_compoundgeeliDrug Delivery Systemslcsh:Organic chemistryDrug DiscoveryPolymer chemistryMoleculeddc:530Physical and Theoretical Chemistryta116drug releaseOrganic ChemistryorganogelcholesterolNuclear magnetic resonance spectroscopyacid-responsiveHydrogen-Ion ConcentrationchemistryChemistry (miscellaneous)in situ gelationDelayed-Action PreparationsDrug deliveryDrug releaseMolecular Medicineorganogel; acid-responsive; cholesterol; <i>in situ</i> gelation; drug releaseGels
researchProduct

Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.

2018

Regulatory guidelines recommend that, when a level A IVIVC is established, dissolution specification should be established using averaged data and the maximum difference between AUC and Cmax between the reference and test formulations cannot be greater than 20%. However, averaging data assumes a loss of information and may reflect a bias in the results. The objective of the current work is to present a new approach to establish dissolution specifications using a new methodology (individual approach) instead of average data (classical approach). Different scenarios were established based on the relationship between in vitro-in vivo dissolution rate coefficient using a level A IVIVC of a cont…

In vitro dissolutionCmaxPharmaceutical Science02 engineering and technologyBioequivalence021001 nanoscience & nanotechnology030226 pharmacology & pharmacyControlled releaseModels Biological03 medical and health sciencesDrug Liberation0302 clinical medicineIVIVCTherapeutic EquivalencyDelayed-Action PreparationsMaximum differenceRange (statistics)Computer Simulation0210 nano-technologyBiological systemDissolutionMonte Carlo MethodMathematicsTabletsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Development of an lbuprofen-Releasing Biodegradable PLA/PGA Electrospun Scaffold for Tissue Regeneration

2009

Our aim was to develop a biodegradable fibrous dressing to act as a tissue guide for in situ wound repair while releasing Ibuprofen to reduce inflammation in wounds and reduce pain for patients on dressing changes. Dissolving the acid form of Ibuprofen (from 1% to 10% by weight) in the same solvent as 75% polylactide, 25% polyglycolide (PLGA) polymers gave uniformly loaded electrospun fibers which gave rapid release of drug within the first 8 h and then slower release over several days. Scaffolds with 10% Ibuprofen degraded within 6 days. The Ibuprofen released from these scaffolds significantly reduced the response of fibroblasts to major pro-inflammatory stimulators. Fibroblast attachment…

KeratinocytesScaffoldPolyglycolidePolyesterswound healingBioengineeringBiocompatible MaterialsIbuprofenbiodegradationApplied Microbiology and Biotechnologychemistry.chemical_compoundTissue engineeringmedicineCell AdhesionHumansdrug releaseCells CulturedCell ProliferationTissue EngineeringTissue ScaffoldsChemistryorganic chemicalsRegeneration (biology)Anti-Inflammatory Agents Non-SteroidalFibroblastsIbuprofenPLGAinflammationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsLiberationWound healingPolyglycolic AcidBiotechnologyBiomedical engineeringmedicine.drug
researchProduct